Vetoquinol, a French veterinary pharmaceutical company, offers a diverse array of products including diagnostics and services, with a specialization in drugs for cattle, dogs, and cats, addressing dermatology, parasitology, osteoarthritis, reproduction, udder health, and respiratory issues. Its portfolio, primarily consisting of off-patent products, stands out for its ease of use and effective delivery.

Prominent offerings include Zyklene for animal anxiety, UpCard for canine heart failure, Tolfine for cattle inflammation, and Falpreva, a comprehensive anti-parasitic for cats.

Just under half of the company's revenue is generated in Europe, with Americas contributing 34% of revenue and Asia-Pacific 18%.